News
Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback